嘉元科技(688388.SH):擬受讓春陽旭陽37.037037%財產份額
格隆匯 3 月 14日丨嘉元科技(688388.SH)公佈,公司擬以自有資金人民幣0.0001萬元受讓深圳春陽創先信息諮詢合夥企業(有限合夥)(“春陽創先”)在深圳春陽旭陽創業投資合夥企業(有限合夥)(“春陽旭陽”)所持有的37.037037%財產份額,對應人民幣1000萬元認繳出資額(未實繳),上述投資且工商變更完成後,公司擁有春陽旭陽財產份額的37.037037%,並按協議規定於2030年12月31日前對該出資份額進行實繳資金。
春陽旭陽將重點關注與公司主營業務相關或能起到一定協同效應的相關標的企業,並通過直接股權投資或從事與股權投資相關的活動,實現合夥企業的投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.